Загрузка...
Suboptimal Responses in Chronic Myeloid Leukemia
The high response rates and increased survival associated with imatinib therapy prompted a paradigm shift in the management of chronic myeloid leukemia. However, 25% to 30% of imatinib-treated patients develop drug resistance or intolerance, increasing the risk of disease progression and poor progno...
Сохранить в:
| Главные авторы: | , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Wiley Subscription Services, Inc., A Wiley Company
2012
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3412948/ https://ncbi.nlm.nih.gov/pubmed/22038681 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.26391 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|